Phase III prostate cancer prevention trials: Are the costs justified?

Ian M. Thompson, Catherine M. Tangen, Eric A. Klein, Scott M. Lippman

Research output: Contribution to journalReview articlepeer-review

18 Scopus citations

Fingerprint

Dive into the research topics of 'Phase III prostate cancer prevention trials: Are the costs justified?'. Together they form a unique fingerprint.

Medicine & Life Sciences